Press release from Business Wire India
Source: Cadila Pharmaceuticals Limited
Monday, November 29, 2010 03:30 PM IST (10:00 AM GMT)
Editors: General: Consumer interest, People, Social issues; Business: Advertising, PR & marketing, Healthcare, biotechnology & pharmaceutical, Household & personal care products & services, Retailers; Healthcare
--------------------------------------------------
Cadila Pharmaceuticals secures Wellcome Trust Award
Wellcome Trust supports Cadila Pharmaceuticals' preventive approach towards combat cardio vascular diseases
Ahmedabad, Gujarat, India, Monday, November 29, 2010 -- (Business Wire India) -- Ahmedabad based pharma major Cadila Pharmaceuticals Limited has received a prestigious Wellcome Trust Award under the new R&D for Affordable Healthcare in India initiative to support a phase III clinical trial of PolycapTM, a combination pill to reduce the risk of Cardiovascular diseases.
Cardio Vascular Diseases (CVD), predominantly heart disease and stroke, account for around 30% of all deaths around the world. The PolycapTM offers a primary prevention strategy to individuals who are at high risk for these illnesses.
PolycapTM comprises three blood pressure reducing agents, including a diuretic and a beta blocker, together with a cholesterol-lowering statin. All of the agents have been chosen based on the evidence of their reducing cardiovascular risk and generic drug status.
The combination pill has already been tested in over 2000 volunteers across 50 centers in India as part of The Indian PolycapTM Study (TIPS) published in the Lancet in 2009. Results from that phase II trial found that use of the drug reduces the risk of coronary heart disease by 62% and stroke by 48%.
Speaking of the award, Mr. Indravadan Modi, Chairman of Cadila Pharmaceuticals said, "We are delighted that our innovative product has gained recognition by the UK's leading biomedical foundation, the Wellcome Trust. This award endorses our efforts in providing research-based revolutionary products in the cardio care segment."
The Wellcome Trust award will support the study of at least 5,000 individuals with no previous history of heart attack or stroke. The placebo-controlled trial will recruit men over the age of 55 and women over 60 that have been identified as being at increased risk of CVD through a questionnaire based on family history and lifestyle factors. The investigators will assess whether taking PolycapTM for a period of five years can cut the risk of CVD, by monitoring the incidence of death due to heart attack, non-fatal heart attack, and non-fatal stroke.
Dr Nick Dunster, Senior Business Analyst at the Wellcome Trust, commented: "Cadila Pharmaceuticals has already reported positive results from previous clinical trials and we look forward to seeing how PolycapTM performs in this larger phase III trial. CVD is a global problem, so a drug that can cut the risk for susceptible individuals has the potential to make a huge impact on human health the world over, not just in India."
About Cadila Pharmaceuticals Ltd.
Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in India and in over 50 countries around the world. It is an integrated healthcare solutions provider with a pharmaceutical product basket in therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The state-of-the-art Research and Development (R&D) facility at Cadila Pharmaceuticals is manned by more than three hundred and fifty scientists. The company also participates in Public-Private partnerships for developing preventive and curative pharmaceutical and diagnostic products. Over the last decade, Cadila Pharmaceuticals has focused on novel approaches to cancer management and is the first Indian company to get multiple investigational new drug applications (INDs) cleared by USFDA. The company has manufacturing facilities conforming to the most stringent international norms at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat; Samba in Jammu and Kashmir and Addis Ababa in Ethiopia. Cadila Pharmaceuticals has recently emerged on the World map with the development of Polycap - a novel and world's first drug combination for prevention of Cardiovascular Heart Disease.
CPL Biologicals is a newly formed company evolved from a joint venture by Cadila Pharmaceuticals Ltd and Novavax, Inc. CPL Biologicals will be developing and manufacturing vaccines, biological therapeutics and diagnostics in India using technology contributed from Novavax and Cadila Pharmaceuticals. In addition, CPL Biologicals will establish manufacturing facilities in India and develop, produce and sell products such as seasonal influenza vaccine and potentially other novel vaccines against dengue fever and chikungunya fever based on Novavax's virus-like-particle (VLP) vaccine technology.
www.cadilapharma.com
About The Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.
www.wellcome.ac.uk
CONTACT DETAILS
Santosh Zokarkar, Cadila Pharmaceuticals Limited, +91 9825883669, santosh.zokarkar@cadilapharma.co.in
Capt Hardeep Sandhu, Cadila Pharmaceuticals Limited, +91 9909971753, hardeep.sandhu@cadilapharma.co.in
Dilip Chauhan, Cadila Pharmaceuticals Limited, +91 9825446010, dilip.chauhan@cadilapharma.co.in
KEYWORDS
CONSUMER, PEOPLE, SOCIAL, MARKETING, HEALTHCARE, HOUSEHOLD, RETAIL, HEALTHCARE
If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.
Submit your press release at http://www.businesswireindia.com
No comments:
Post a Comment